~~<i id='DFAA1928EE'><strike id='DFAA1928EE'><tt id='DFAA1928EE'><pre id='DFAA1928EE'></pre></tt></strike></i>~~

Home» explore» Wikipedia

Wikipedia

author：knowledge 2025-09-29 16:57:07 Page View：7317

CMS Administrator Chiquita Brooks-LaSure Chip Somodevilla/Getty Images

WASHINGTON — Eli Lilly’s latest anti-amyloid Alzheimer’s treatment seems to slow the disease, the company announced this week — news that adds even more pressure on Medicare’s unprecedented restrictions on coverage.

Medicare has so far held firm on its plans to require patient registries for the entire class of anti-amyloid Alzheimer’s drugs, even after they are fully approved.

Pharmaceutical groups and patient advocates are increasingly fighting that approach.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： People can get long Covid without testing positive for virus: Study
Next article： Medical records are filled with copy

focus

Hollywood unions extend contract negotiations for actors

1:36HollywoodwritersandtheirsupportersfromtheSAGAFTRAactors'unionwalkthepicketlineoutsideWarnerBrosS

How to make over

AdobeTheFoodandDrugAdministrationrecentlyapprovedOpill,thefirstover-the-counteraccessbirthcontrolpil

Medicare proposal to cover medical devices draws a mixed reaction

AdobeThemedicaldeviceindustryissplitonwhetheraproposednewMedicarereimbursementpathwaywilldoanythingt

Vivek Ramaswamy made waves in the debate, much as in biotech

BusinessmanVivekRamaswamyandformerU.N.AmbassadorNikkiHaleyAPPhoto/MorryGashTheyoungestcandidateonWed